Sunday, May 26, 2024
Facebook Linkedin Twitter
HomeTagsADC

ADC

Biotechnology

Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients With Advanced Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial

News Desk -
Positive high-level results from the TROPION-Lung01 Phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the dual primary endpoint of...
Biotechnology

Corbus Pharmaceuticals expands oncology pipeline with the addition of a clinical stage Nectin-4 targeting Antibody Drug Conjugate (ADC)

PR Newswire -
Corbus Pharmaceuticals Holdings, Inc, a precision oncology company, announced that it has entered into an exclusive licensing agreement with CSPC Megalith Biopharmaceutical Co., Ltd,...
Biotechnology

Nona Biosciences Enters into HCAb Based Antibody Discovery Collaboration Agreement with Mythic Therapeutics

PR Newswire -
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited committed to cutting edge technology innovations, and providing a total solution from "Idea to IND"...
Automotive

Pony.ai Autonomous Driving Controller Built on NVIDIA DRIVE Orin, Set for Mass Production

Business Wire -
Pony.ai, a leading global autonomous driving technology company, announced that its Autonomous Driving Controller (ADC), powered by the NVIDIA DRIVE Hyperion compute architecture (DRIVE...
Biotechnology

CStone Pharmaceuticals announced the IND approval of CS5001, a potential global best-in-class ROR1-targeting ADC by the U.S. Food and Drug Administration

PR Newswire -
CStone Pharmaceuticals, a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics

Load more
ReadMagazine © | All rights reserved |Contact Us | Privacy Policy| Become A Guest Writer | Advertise with Us